Patents by Inventor Carsten Korth

Carsten Korth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050049395
    Abstract: The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrPC and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosqvated PrP is generated de novo and can be detected by standard immunoblot techniques.
    Type: Application
    Filed: June 23, 2004
    Publication date: March 3, 2005
    Inventors: Stanley Prusiner, Carsten Korth
  • Publication number: 20050020582
    Abstract: The invention is drawn to compositions and methods for inhibiting and treating malformed forms of proteins causing neurodegenerative disease, such as protease resistant prion proteins (PrPSc) and those associated with transmissible spongiform encephalopathies (TSEs). The compounds disclosed herein can be present as racemic mixtures or as compositions consisting essentially only of the optically active isomer in a higher percentage amount e.g. 60% or more, 70% or more, 80% or more, 90% or more or 100% of the optically active isomer and specifically the dextrorotary isomer of quinacrine.
    Type: Application
    Filed: May 23, 2002
    Publication date: January 27, 2005
    Inventors: Stanley Prusiner, Carsten Korth, Barnaby May
  • Publication number: 20040229898
    Abstract: The invention is drawn to compositions and methods for inhibiting and treating malformed forms of proteins causing neurodegenerative disease, such as protease resistant prion proteins (PrPSc) and those associated with transmissible spongiform encephalopathies (TSEs). Bis-acridines are characterized by a dimeric motif, comprising two acridine heterocycles tethered by a linker. A library of bis-(6-chloro-2-methoxy-acridin-9-yl) and bis-(7-chloro-2-methoxy-benzo[b][1,5]naphthyridin-10-yl) analogs were synthesized to explore the effect of structurally diverse linkers on PrPSc replication in ScN2a cells. Structure-activity analysis revealed that linker length and structure effect inhibition of prion replication in cultured, scrapied cells.
    Type: Application
    Filed: November 25, 2003
    Publication date: November 18, 2004
    Applicant: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Carsten Korth, Barnaby C.H. May
  • Patent number: 6767712
    Abstract: The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrPC and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 27, 2004
    Assignee: The Regents of the University of California
    Inventors: Stanley B. Prusiner, Carsten Korth
  • Patent number: 6765088
    Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: July 20, 2004
    Assignee: Universität Zürich
    Inventors: Carsten Korth, Beat Stierli, Peter Stregt, Bruno Oesch, Markus Moser
  • Patent number: 6346376
    Abstract: This document describes an optical sensor unit and a procedure for the specific detection and identification of biomolecules at high sensitivity in real fluids and tissue homogenates. High detection limits are reached by the combination of i) label-free integrated optical detection of molecular interactions, ii) the use of specific bioconstituents for sensitive detection and iii) planar optical transducer surfaces appropriately engineered for suppression of non-specific binding, internal referencing and calibration. Applications include the detection of prion proteins and identification of those biomolecules which non-covalently interact with surface immobilized prion proteins and are intrinsically involved in the cause of prion related disease.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: February 12, 2002
    Assignee: Centre Suisse d'Electronique et de Mictotechnique SA
    Inventors: Hans Sigrist, Hui Gao, Rino E. Kunz, Jürg Dübendorfer, Carsten Korth, Markus Moser, Bruno Oesch
  • Publication number: 20020004938
    Abstract: The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrPC and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.
    Type: Application
    Filed: June 28, 2001
    Publication date: January 10, 2002
    Inventors: Stanley B. Prusiner, Carsten Korth